Reprogramming T cells and hematopoietic cells
US10221396B2 · kind B2 · utility
10Cited by
9References
44Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 26, 2017 |
| Grant date | Mar 5, 2019 |
| Priority date | — |
| Expiry date | Apr 26, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02E60/10
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Methods and compositions relating to the production of induced pluripotent stem cells (iPS cells) are disclosed. For example, induced pluripotent stem cells may be generated from CD34+ hematopoietic cells, such as human CD34+ blood progenitor cells, or T cells. Various iPS cell lines are also provided. In certain embodiments, the invention provides novel induced pluripotent stem cells with a genome comprising genetic rearrangement of T cell receptors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.